Neil Littman
InvestorManaging Partner at Bioverge
San Francisco, California
Writes $100K – $5M checks · typically $1.5M
About
Neil Littman is Vice President of Early Portfolio Development at 4D Molecular Therapeutics, where he leads strategic partnerships in pulmonology programs. He previously served as CEO of ReIGNITE Therapeutics, where he advanced an oncolytic immunotherapy platform, and founded Bioverge, a venture platform through which he invested in over 40 early-stage healthcare companies. His career includes roles at the California Institute for Regenerative Medicine managing a $3 billion fund, as VP of Business Development at Notable Labs, and in healthcare investment banking and venture investing.
Experience
- 4D Molecular TherapeuticsVice President, Early Portfolio Developmentcurrent2026 — present
- 4D Molecular TherapeuticsVice President, Alliance Management2026San Francisco Bay Area
- ReIGNITE Therapeutics, Inc.Board Observercurrent2026 — present
- ReIGNITE Therapeutics, Inc.Chief Executive Officer2024 — 2026
- ReIGNITE Therapeutics, Inc.Chief Business Officer2023 — 2024San Francisco Bay Area
- Riverine VenturesVenture Partnercurrent2022 — present
- Bioverge VenturesFounder & Managing Partnercurrent2020 — presentSan Francisco Bay Area
- NotableVice President Of Business Development2018 — 2020San Francisco Bay Area
- California Institute for Regenerative MedicineDirector, Business Development2012 — 2018San Francisco Bay Area
- Burrill & CompanyHealthcare Investment Banking, Senior Associate2009 — 2012San Francisco Bay Area
- Brickford Asset Management LLCCo-founder and Managing Partner2007 — 2009San Francisco Bay Area
- Thomas Weisel PartnersHealthcare Investment Banking, Financial Analyst2005 — 2007New York
- Deutsche BankHealthcare Investment Banking, Financial Analyst2004 — 2005New York
Skills & more
Public Speaking1NegotiationCommunicationStrategy14Management1LeadershipStrategic PlanningDeal StructuringLead GenerationFundraising2Executive Management1Investment Banking26
+12 more
Venture CapitalBiotechnologyLifesciencesStart-upsTechnology TransferCorporate DevelopmentPortfolio ManagementBiopharmaceuticalsPrivate EquityCorporate FinanceDue DiligenceFinancial ModelingFrom Neil's professional profile.
Colleagues at Bioverge
Frequently asked questions
- Who is Neil Littman?
- Neil Littman is Vice President of Early Portfolio Development at 4D Molecular Therapeutics, where he leads strategic partnerships in pulmonology programs. He previously served as CEO of ReIGNITE Therapeutics, where he advanced an oncolytic immunotherapy platform, and founded Bioverge, a venture platform through which he invested in over 40 early-stage healthcare companies. His career includes roles at the California Institute for Regenerative Medicine managing a $3 billion fund, as VP of Business Development at Notable Labs, and in healthcare investment banking and venture investing.
- Where does Neil Littman work?
- Neil Littman is Managing Partner at Bioverge.
- What check size does Neil Littman write?
- Neil Littman typically writes checks of $100K – $5M.
- Where did Neil Littman go to school?
- Neil Littman studied at The Johns Hopkins University (Master of Science (M.S.), Biotechnology); University of Colorado Boulder (B.A., Molecular).
Same school
Also attended The Johns Hopkins University261
Wes NicholsPartner at March Capital PartnersDemi ObayomiPrincipal at Sapphire VenturesJun JeonInvestor at Khosla VenturesNicole FraenkelInvestor at Khosla VenturesElena VibochManaging Director at General CatalystScott RubinVenture Partner at Lux Capital
+ 255 more
Also attended University of Colorado Boulder178
Steve WozniakCo-founder of AppleChris RustCo-Founder and Partner at Clear VenturesSydney EberhardtInvestor at True VenturesBob ThomasPartner at OxxKirsten SuddathInvestor at Next Frontier CapitalJeff RoseAdvisor at AI Capital
+ 172 more
